SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ribi Immunochem (ribi)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kathleen who wrote (68)3/26/1998 9:56:00 AM
From: Bill Tomko  Read Replies (1) of 92
 
This while postive, is no big deal in and of itself. IntronA is approved drug for mel. Melacine has completed Phase III (July 1994) and found to be safe and effective. Accordingly this trial is one determining if an synergistic beifit occures when they are combined. Normally an Phase II trial would only be terminated for safety concerns. Sudden safety issues in a phase III trail of an approved drug and a drug which had completed phaseIII would be very unlikly.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News